Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease

被引：3

作者：

Sedano Munoz, Rocio ^{[1
]}

Quera Pino, Rodrigo ^{[2
,3
]}

Lubascher Correa, Jaime ^{[2
,3
]}

Pizarro Jofre, Gonzalo ^{[2
,3
]}

Simian Marin, Daniela ^{[2
,4
]}

机构：

[1] Hosp Clin Univ Chile, Serv Gastroenterol, Santiago, Chile

[2] Clin Las Condes, Programa Enfermedad Inflamatoria Intestinal, Santiago, Chile

[3] Clin Las Condes, Dept Gastroenterol, Santiago, Chile

[4] Clin Las Condes, Subdirecc Acad, Santiago, Chile

来源：

GASTROENTEROLOGIA Y HEPATOLOGIA | 2019年 / 42卷 / 02期

关键词：

Inflammatory bowel disease; Anti-tumour necrosis factor; Infliximab; Adalimumab; Treatment withdrawal; CROHNS-DISEASE; MAINTENANCE TREATMENT; CLINICAL REMISSION; INFLIXIMAB MAINTENANCE; COMBINATION THERAPY; ULCERATIVE-COLITIS; LONG; DISCONTINUATION; ADALIMUMAB; WITHDRAWAL;

D O I：

10.1016/j.gastrohep.2018.10.010

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Anti-tumour necrosis factor a therapy in inflammatory bowel disease has been shown to be effective in clinical practice. After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these therapies, and how this should be done. This review aims to evaluate the current evidence on these topics concerning anti-tumour necrosis factor a therapies, and eventually identify conditions and subgroups of patients that could potentially be candidates for withdrawal. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：133 / 140

页数：8

共 50 条

[1] De-escalation of Therapy in Inflammatory Bowel Disease
Frias Gomes C.
Colombel J.-F.
Torres J.
[J]. Current Gastroenterology Reports, 2018, 20 (8)
[2] De-escalation of medical therapy in inflammatory bowel disease
Gomes, Catarina Frias
Chapman, Thomas P.
Satsangi, Jack
[J]. CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 73 - 81
[3] De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease
Miyatani, Yusuke
Kobayashi, Taku
[J]. GUT AND LIVER, 2023, 17 (02) : 181 - 189
[4] De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
Chapman, Thomas P.
Gomes, Catarina Frias
Louis, Edouard
Colombel, Jean-Frederic
Satsangi, Jack
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (01): : 63 - 79
[5] Success rate of dose de-escalation in patients with inflammatory bowel disease treated with intensified anti-TNF therapy
Viazis, N.
Anastasiou, J.
Koukouratos, T.
Giakoumis, M.
Anastasopoulos, E.
Chanias, M.
Markoglou, K.
Karamanolis, D.
[J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S56 - S56
[6] De-escalation of biological therapy in inflammatory bowel disease: Benefits and risks
Fredericks, E.
Watermeyer, G.
[J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2019, 109 (10): : 745 - 749
[7] De-escalation of Combination Drug Therapy in Inflammatory Bowel Disease Patients
Saleh, Adam A.
Waghela, Rajdeepsingh
Garza, Manuel
Stading, Rachel
Miroballi, Natalia
Moskow, Joshua
Thurston, Theresa
Abraham, Bincy
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S722 - S722
[8] De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation
Thomas, P.
Smits, L.
Groen, M. Te
West, R.
Russel, M.
Jansen, J.
Romkens, T.
Hoentjen, F.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S086 - S086
[9] IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
Strobel, Thomas
Ahmed, Waseem
De la Sancha, Carlo
Bohm, Matthew
Fischer, Monika
[J]. ACG CASE REPORTS JOURNAL, 2020, 7 (09)
[10] De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
Thomas, Pepijn W. A.
Smits, Lisa J. T.
Te Groen, Maarten
West, Rachel L.
Russel, Maurice G. V. M.
Jansen, Jeroen M.
Romkens, Tessa E. H.
Hoentjen, Frank
[J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (05) : 488 - 495

← 1 2 3 4 5 →